The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer

References

• Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC cancerbase no. 11 [internet]. Lyon, France: International Agency for Research on Cancer; 2013. cited 2013 Dec . Available from: http://globocan.iarc.fr (link is external)
   Google Scholar
• Ettinger DS, Akerley W, Bepler G, et al. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8(7):740–801. Available from: http://www.jnccn.org/content/8/7/740.short
   PubMed Web of Science ®Google Scholar
• Gainor JF, Varghese AM, Ou SHI, et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res. 2013;19(15):4273–4281. DOI:10.1158/1078-0432.CCR-13-0318
   PubMed Web of Science ®Google Scholar
• Sholl LM, Aisner DL, Varella-Garcia M, LCMC Investigators; et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015 May;10(5):768–777.
   PubMed Web of Science ®Google Scholar
• Toyokawa G, Seto T. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance. Respir Investig. 2014;52(6):330–338.
   PubMedGoogle Scholar
• Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol. 2008;3(1):13–17. DOI:10.1097/JTO.0b013e31815e8b60
   PubMed Web of Science ®Google Scholar
• Liao B-C, Lin -C-C, Shih J-Y, et al. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol. 2015;7(5):274–290. DOI:10.1177/1758834015590593
   PubMed Web of Science ®Google Scholar
• Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol. 2011;35(8):1226–1234.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology non-small cell lung cancer. Version 4.2016. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf
   Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in Non-Hodgkin’s lymphoma. Science. 1994;263(5151):1281–1284.
   PubMed Web of Science ®Google Scholar
• Grande E, Bolós M-V, Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther. 2011;10(4):569–579. DOI:10.1158/1535-7163.MCT-10-0615
   PubMed Web of Science ®Google Scholar
• Kanaan Z, Kloecker GH, Paintal A, et al. Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond. Onco Targets Ther. 2015;8:885–892. DOI:10.2147/OTT.S67262
   PubMed Web of Science ®Google Scholar
• Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer. 2013;13(10):685–700.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–566. DOI:10.1038/nature05945
   PubMed Web of Science ®Google Scholar
• Sasaki T, Koivunen J, Ogino A, et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res. 2011;71(18):6051–6060. DOI:10.1158/0008-5472.CAN-11-1340.
   PubMed Web of Science ®Google Scholar
• Iacono D, Chiari R, Metro G, et al. Future options for ALK-positive non-small cell lung cancer. Lung Cancer. 2015;87(3):211–219.
   PubMed Web of Science ®Google Scholar
• Cajaiba MM, Jennings LJ, Rohan SM, et al. ALK-rearranged renal cell carcinomas in children. Genes Chromosomes Cancer. 2016 May;55(5):442–451.
   PubMed Web of Science ®Google Scholar
• Costigan DC, Doyle LA. Advances in the clinicopathological and molecular classification of cutaneous mesenchymal neoplasms. Histopathology. 2016 May;68(6):776–795.
   PubMed Web of Science ®Google Scholar
• Ying J, Lin C, Wu J, et al. Anaplastic lymphoma kinase rearrangement in digestive tract cancer: implication for targeted therapy in Chinese population. PLoS One. 2015 Dec 17;10(12):e0144731.
   PubMed Web of Science ®Google Scholar
• Cameron L, Solomon B. Treatment of ALK-rearranged non-small cell lung cancer: recent progress and future directions. Drugs. 2015 Jul;75(10):1059–1070.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol. 2009;27(26):4247–4253.
   PubMed Web of Science ®Google Scholar
• Guérin A, Sasane M, Zhang J, et al. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer. Cancer Epidemiol. 2015 Jun;39(3):307–312.
   PubMed Web of Science ®Google Scholar
• Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the college of american pathologists, international association for the study of lung cancer, and association for molecular pathology. J Thorac Oncol. 2013;8(7):823–859.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Vysis ALK break apart FISH probe kit, with the vysis paraffin pretreatment IV and post hybridization wash buffer kit, ProbeChek ALK negative control slides, and ProbeChek ALK positive control slides. Available from: http://www.accessdata.fda.gov/cdrh_docs/pdf11/p110012a.pdf
   Google Scholar
• Selinger CI, Rogers TM, Russell PA, et al. Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. Mod Pathol. 2013;26:1545–1553.
   PubMed Web of Science ®Google Scholar
• Rogers TM, Russell PA, Wright G, et al. Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. J Thorac Oncol. 2015 Apr;10(4):611–618.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. VENTANA ALK (D5F3) CDX ASSAY approval order. 2015 Apr. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P140025
   Google Scholar
• Carneiro B, Costa R, Taxter T, et al. Is personalized medicine here? Oncology (Willinston Park). 2016 Apr;30(4):293–303.
   PubMed Web of Science ®Google Scholar
• Pailler E, Adam J, Barthélémy A, et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2013 Jun 20;31(18):2273–2281.
   PubMed Web of Science ®Google Scholar
• Costa DB. Identification of somatic genomic alterations in circulating tumors cells: another step forward in non-small-cell lung cancer? J Clin Oncol. 2013 Jun 20;31(18):2236–2239.
   PubMed Web of Science ®Google Scholar
• Hamilton G, Rath B, Burghuber O. Pharmacokinetics of crizotinib in NSCLC patients. Expert Opin Drug Metab Toxicol. 2015;11(5):835–842. DOI:10.1517/17425255.2015.1021685
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28;363(18):1693–1703.
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013 Jun 20;368(25):2385–2394.
   PubMed Web of Science ®Google Scholar
• Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167–2177. DOI:10.1056/NEJMoa1408440
   PubMed Web of Science ®Google Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. Concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):443–445.
   PubMed Web of Science ®Google Scholar
• Weickhardt AJ, Dmedsc M, Scheier B, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitos in oncogene addicted non-small cell lung cancer. J Thorac Oncol. 2012;7(12):1807–1814.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2014;18:1472–1482.
   Web of Science ®Google Scholar
• Choi YL, Soda M, Yamashita Y, ALK Lung Cancer Study Group; et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010;363(18):1734–1739.
   PubMed Web of Science ®Google Scholar
• Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged kung cancers. Sci Transl Med. 2012;4(120):120ra17.
   PubMed Web of Science ®Google Scholar
• Friboulet L, Li N, Katayama R, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014;4(6):662–673. DOI:10.1158/2159-8290.CD-13-0846.
   PubMed Web of Science ®Google Scholar
• Katayama R, Friboulet L, Koike S, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res. 2014;20(22):5686–5696. DOI:10.1158/1078-0432.CCR-14-1511.
   PubMed Web of Science ®Google Scholar
• Lovly CM, McDonald NT, Chen H, et al. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med. 2014;20:1027–1034.
   PubMed Web of Science ®Google Scholar
• Kogita A, Togashi Y, Hayashi H, et al. Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition. Int J Oncol. 2014 Oct;45(4):1430–1436.
   PubMed Web of Science ®Google Scholar
• Song Z, Wang M, Zhang A. Alectinib: a novel second generation anaplastic lymphoma kinase (ALK) inhibitor for overcoming clinically-acquired resistance. Acta Pharm Sin B. 2015 Jan;5(1):34–37.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011;19(5):679–690. DOI:10.1016/j.ccr.2011.04.004
   PubMed Web of Science ®Google Scholar
• Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol. 2014;74(5):1023–1028. DOI:10.1007/s00280-014-2578-6
   PubMed Web of Science ®Google Scholar
• Kodama T, Tsukaguchi T, Yoshida M, et al. Selective ALK-inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett. 2014;351:215–221.
   PubMed Web of Science ®Google Scholar
• Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small cell lung cancer (AF-001JP study): a single arm, open-lable, phase 1-2 study. Lancet Oncol. 2013;14:590–598.
   PubMed Web of Science ®Google Scholar
• Gadgeel S, Gandhi L, Riely GI, et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small cell lung scancer (AF-002GJ): results from the dose-finding portion of phase 1/2 study. Lancet Oncol. 2014;15:1119–1128.
   PubMed Web of Science ®Google Scholar
• Shaw A, Ghandi L, Gadgeel S, et al. Alectinib in ALK-positive, crizotinib-resistant, non-small cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol. 2016;17:234–242.
   PubMed Web of Science ®Google Scholar
• Ou S, Ahn JS, Petris LD, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small cell lung cancer: a phase II global study. J Clin Oncol. 2015 Nov 23. published online. DOI:10.1200/JCO.2015.63.9443
   Web of Science ®Google Scholar
• Crinò L, Ahn MJ, De Marinis F, et al. Multicenter phase ii study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2. J Clin Oncol. 2016 Aug 20;34(24):2866–2873.
   Google Scholar
• Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. Lancet Oncol. 2016 Apr;17(4):452–463.
   PubMed Web of Science ®Google Scholar